Abbott Laboratories (ABT) stock
NYSE
As of the Nov 5, 2026 close (U.S. Eastern)
- Market cap
- $196.8B
- As of Nov 5, 2026
- P/E
- 41.85x
- Trailing twelve months
- P/B
- 3.86x
- Latest reported equity
- P/S
- 4.08x
- Trailing twelve months
- ROE
- 9.2%
- Trailing twelve months
- Dividend yield
- 2.11%
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
- Market cap
- $196.8B
- As of Nov 5, 2026
- P/E
- 41.85x
- Trailing twelve months
- P/B
- 3.86x
- Latest reported equity
- P/S
- 4.08x
- Trailing twelve months
- ROE
- 9.2%
- Trailing twelve months
- Dividend yield
- 2.11%
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 5, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
41.85x
P/B
3.86x
P/S
4.08x
Earnings and dividend metrics▾
Earnings
EPS
$2.71
Earnings per share
BPS
$29.46
Book value per share
ROE
9.2%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $2.71 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $29.46 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 9.2%.
Dividends
Yield
2.11%
Dividend per share
$2.40
Payout ratio
87.6%
Consecutive years
4+ yrs
Yield uses fiscal 2025 dividends · Dividend per share and payout ratio are for fiscal 2025.
- Dividend yield — dividends divided by the share price (or market cap). It falls when the price rises.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about $240.00 before tax.
- Payout ratio — 87.6% of earnings was paid out as dividends.
- Consecutive years — dividends were paid every year for more than 4 years. That does not mean they will continue.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 14.5% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $11.4B+14.5%
$10.6B
Jul–Sep '24
$11.4B
Jul–Sep '25
$13B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 4, 2026.
- Earnings per share decreased 43.6% from the same quarter a year earlier.
- Revenue increased 14.5% from the same quarter a year earlier.
- Operating income decreased 34.0% from the same quarter a year earlier.
- Net income decreased 44.0% from the same quarter a year earlier.
Filed Nov 4, 2026 · 10-Q · SEC EDGAR · View original
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Conroy Kevin TDirector · Sep 23, 2026Shares withheld for taxes52,507 shares · $5.5MAvg. price $103.9981,230 shares held after
- MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLER · Sep 2, 2026Open-market sale27 shares · $3KAvg. price $109.5424,549 shares held after
- Boudreau Philip PEVP AND CFO · Sep 1, 2026Shares withheld for taxes388 shares · $43KAvg. price $110.3670,784 shares held after
- MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLER · Sep 1, 2026Shares withheld for taxes52 shares · $6KAvg. price $110.3624,576 shares held after
- Ford Robert BCHAIRMAN AND CEO · Aug 25, 2026Open-market sale398,832 shares · $46.2MAvg. price $115.8503
Show 2 price lots
- 218,535 shares × $115.57$25.3M
- 180,297 shares × $116.19$20.9M
- Ford Robert BCHAIRMAN AND CEO · Aug 25, 2026Option exercise398,832 shares · $21.5MAvg. price $54.0226
Show 2 price lots
- 246,963 shares × $59.94$14.8M
- 151,869 shares × $44.4$6.7M
- Morrone Louis H.EXECUTIVE VICE PRESIDENT · Aug 12, 2026Other12 shares · $1KAvg. price $107.990 shares held after
- Morrone Louis H.EXECUTIVE VICE PRESIDENT · Aug 11, 2026Open-market sale5,850 shares · $643KAvg. price $109.8370,724 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary10-QThe company said total net sales rose 14.8% in Q3 2026 excluding the impact of foreign exchange. It attributed the increase to the acquisition of Exact Sciences Corporation and high single-digit growth in Medical Devices and Established Pharmaceutical Products.Published Nov 4, 2026 · Filed Nov 4, 2026Read the summary →
- AI summary8-KThe company said it plans to separate its Nutrition business into an independent, publicly traded company on October 21, 2026. It said the separation would be made through a distribution of shares to Abbott shareholders and is intended to qualify as tax-free for U.S. federal income tax purposes.Published Oct 21, 2026 · Filed Oct 21, 2026Read the summary →
- AI summary8-KThe company said net sales for Q3 2026 were $13,013 million, up 14.5% on a reported basis and 7.0% on a comparable basis. GAAP net earnings were $920 million, and GAAP diluted EPS was $0.53.Published Oct 21, 2026 · Filed Oct 21, 2026Read the summary →
- The company said total net sales rose 14.8% in Q3 2026 excluding the impact of foreign exchange. It attributed the increase to the acquisition of Exact Sciences Corporation and high single-digit growth in Medical Devices and Established Pharmaceutical Products.Read the full analysis →
- The company said net sales for Q3 2026 were $13,013 million, up 14.5% on a reported basis and 7.0% on a comparable basis. GAAP net earnings were $920 million, and GAAP diluted EPS was $0.53.Read the full analysis →
- The company said it plans to separate its Nutrition business into an independent, publicly traded company on October 21, 2026. It said the separation would be made through a distribution of shares to Abbott shareholders and is intended to qualify as tax-free for U.S. federal income tax purposes.Read the full analysis →
- The company said net sales excluding the impact of foreign exchange rose 12.2% in Q2 2026, citing the acquisition of Exact Sciences Corporation and high single-digit growth in Medical Devices and Established Pharmaceutical Products. Nutritional Products sales declined.Read the full analysis →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Abbott Laboratories (ABT) stock information
NYSE
Abbott Laboratories (ABT) is listed on NYSE. Its market capitalization is about $196.8B. On trailing-twelve-month earnings the P/E ratio is 41.85, and the P/B ratio is 3.86. Return on equity is 9.2%. These figures are computed in-house from official filings and are reference information only.
Abbott Laboratories — frequently asked questions
- What is the P/E ratio of Abbott Laboratories (ABT)?
- On a trailing-twelve-month basis, ABT trades at a P/E ratio of 41.85. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Abbott Laboratories?
- ABT has a market capitalization of about $196.8B. The figure moves with the share price and is refreshed each trading day.
- Does Abbott Laboratories pay a dividend?
- ABT has a dividend yield of about 2.11%, based on disclosed payment history. Dividend policy can change; this is reference information only.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.